Monoclonal antibodies against EGFR are commonly used in the treatment of metastatic colorectal cancer, and some of these agents synergistically inhibit both EGFR phosphorylation and ABCG2 drug efflux activity [67,68,69]. This evidence concerns the gene EGFR and metastatic colorectal cancer.